Corxel raises $287m as obesity continues to spark investor interest
Corxel Pharmaceuticals has raised $287m to fund its suite of cardiometabolic assets, signifying that investor appetite for weight loss drug…
23 Jan 2026
Daiichi Sankyo and AstraZeneca’s Enhertu gains NMPA approval for HER2 GEJ
Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has received approval from China’s National Medical Products Administration (NMPA) for adults with locally advanced or metastatic human epidermal growth factor receptor 2…
22 Jan 2026
BMS bets on Janux’s novel solid tumour therapy through $850m deal
Bristol Myers Squibb (BMS) has added to its oncology pipeline through an exclusive global licensing agreement with Janux Therapeutics. This deal will see the pair co-develop a novel therapy for…
22 Jan 2026
US set to officially exit WHO in culmination of Trump’s domestic push
The US is poised to leave the World Health Organization (WHO) as the one-year countdown of legal notice comes to an end, despite warnings from the agency’s chief on adverse…
22 Jan 2026
Heart disease and stroke deaths take a downturn, AHA report reveals
A new report from the American Heart Association (AHA) has found that US cardiovascular disease (CVD)-related deaths declined between 2022 and 2023 – bucking a five-year upward trend. Published in…
22 Jan 2026
Johnson & Johnson reports 9.1% increase in sales for Q4 2025
Johnson & Johnson (J&J) has reported a 9.1% increase in sales for Q4 2025, reaching $24.56bn, with net earnings rising by 49.1% to $5.11bn. For the entire year, sales grew…
22 Jan 2026
Opna Bio’s OPN-2853 secures FDA’s orphan drug status for myelofibrosis
Opna Bio has received the US Food and Drug Administration’s (FDA) orphan drug designation for OPN-2853 (zavabresib), a bromodomain and extra-terminal motif (BET) small molecule inhibitor, to treat myelofibrosis. The…